Literature DB >> 33807511

Phosphodiesterases Expression during Murine Cardiac Development.

Thays Maria da Conceição Silva Carvalho1, Silvia Cardarelli1, Mauro Giorgi2, Andrea Lenzi3, Andrea M Isidori3, Fabio Naro1.   

Abstract

3'-5' cyclic nucleotide phosphodiesterases (PDEs) are a large family of enzymes playing a fundamental role in the control of intracellular levels of cAMP and cGMP. Emerging evidence suggested an important role of phosphodiesterases in heart formation, but little is known about the expression of phosphodiesterases during cardiac development. In the present study, the pattern of expression and enzymatic activity of phosphodiesterases was investigated at different stages of heart formation. C57BL/6 mice were mated and embryos were collected from 14.5 to 18.5 days of development. Data obtained by qRT-PCR and Western blot analysis showed that seven different isoforms are expressed during heart development, and PDE1C, PDE2A, PDE4D, PDE5A and PDE8A are modulated from E14.5 to E18.5. In heart homogenates, the total cAMP and cGMP hydrolytic activity is constant at the evaluated times, and PDE4 accounts for the majority of the cAMP hydrolyzing ability and PDE2A accounts for cGMP hydrolysis. This study showed that a subset of PDEs is expressed in developing mice heart and some of them are modulated to maintain constant nucleotide phosphodiesterase activity in embryonic and fetal heart.

Entities:  

Keywords:  cyclic nucleotides; heart development; phosphodiesterases

Mesh:

Substances:

Year:  2021        PMID: 33807511      PMCID: PMC7961729          DOI: 10.3390/ijms22052593

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  38 in total

1.  Quantitative evaluation of ontogenetic change in heart rate and its autonomic regulation in newborn mice with the use of a noninvasive piezoelectric sensor.

Authors:  Shinichi Sato
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-02-08       Impact factor: 4.733

2.  Phosphodiesterase 8A (PDE8A) regulates excitation-contraction coupling in ventricular myocytes.

Authors:  Enrico Patrucco; Masami Shimizu Albergine; Luis F Santana; Joseph A Beavo
Journal:  J Mol Cell Cardiol       Date:  2010-03-28       Impact factor: 5.000

3.  PDE1C deficiency antagonizes pathological cardiac remodeling and dysfunction.

Authors:  Walter E Knight; Si Chen; Yishuai Zhang; Masayoshi Oikawa; Meiping Wu; Qian Zhou; Clint L Miller; Yujun Cai; Deanne M Mickelsen; Christine Moravec; Eric M Small; Junichi Abe; Chen Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-20       Impact factor: 11.205

Review 4.  Cardiac Regeneration: Lessons From Development.

Authors:  Francisco X Galdos; Yuxuan Guo; Sharon L Paige; Nathan J VanDusen; Sean M Wu; William T Pu
Journal:  Circ Res       Date:  2017-03-17       Impact factor: 17.367

5.  Phosphodiesterase 4D is required for beta2 adrenoceptor subtype-specific signaling in cardiac myocytes.

Authors:  Yang Xiang; Fabio Naro; Maria Zoudilova; S-L Catherine Jin; Marco Conti; Brian Kobilka
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-11       Impact factor: 11.205

Review 6.  Histology atlas of the developing mouse heart with emphasis on E11.5 to E18.5.

Authors:  Saija M Savolainen; Julie F Foley; Susan A Elmore
Journal:  Toxicol Pathol       Date:  2009-04-09       Impact factor: 1.902

7.  Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice.

Authors:  Peter Pokreisz; Sara Vandenwijngaert; Virginie Bito; An Van den Bergh; Ilse Lenaerts; Cornelius Busch; Glenn Marsboom; Olivier Gheysens; Pieter Vermeersch; Liesbeth Biesmans; Xiaoshun Liu; Hilde Gillijns; Marijke Pellens; Alfons Van Lommel; Emmanuel Buys; Luc Schoonjans; Johan Vanhaecke; Erik Verbeken; Karin Sipido; Paul Herijgers; Kenneth D Bloch; Stefan P Janssens
Journal:  Circulation       Date:  2009-01-12       Impact factor: 29.690

Review 8.  Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system.

Authors:  Donald H Maurice; Daniel Palmer; Douglas G Tilley; Heather A Dunkerley; Stuart J Netherton; Daniel R Raymond; Hisham S Elbatarny; Sandra L Jimmo
Journal:  Mol Pharmacol       Date:  2003-09       Impact factor: 4.436

Review 9.  cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology.

Authors:  Manuela Zaccolo; Matthew A Movsesian
Journal:  Circ Res       Date:  2007-06-08       Impact factor: 17.367

10.  Generation and phenotypic characterization of Pde1a mutant mice.

Authors:  Xiaofang Wang; Satsuki Yamada; Wells B LaRiviere; Hong Ye; Jason L Bakeberg; María V Irazabal; Fouad T Chebib; Jan van Deursen; Peter C Harris; Caroline R Sussman; Atta Behfar; Christopher J Ward; Vicente E Torres
Journal:  PLoS One       Date:  2017-07-27       Impact factor: 3.240

View more
  1 in total

1.  The Effects of Acute and Chronic Selective Phosphodiesterase 1 Inhibition on Smooth Muscle Cell-Associated Aging Features.

Authors:  Keivan Golshiri; Ehsan Ataei Ataabadi; Annika A Jüttner; Gretchen L Snyder; Robert E Davis; Amy Lin; Lei Zhang; René de Vries; Ingrid M Garrelds; Frank P J Leijten; A H Jan Danser; Anton J M Roks
Journal:  Front Pharmacol       Date:  2022-01-31       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.